IOL Chemicals and Pharmaceuticals announced its financial results for the quarter and nine months ended 31st December, 2025.

Commenting on the performance, Vikas Gupta, Joint Managing Director, IOL Chemicals and Pharmaceuticals, said, “Q3 FY26 has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion and a 39 percent YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses.

“Our pharmaceuticals segment continues to lead growth, delivering an 18 percent revenue increase year-on-year. Importantly, pharma’s share of overall revenue has risen from 57 percent in Q3 FY25 to 61 percent in Q3 FY26, highlighting its growing contribution. Earnings Before Interest and Taxes (EBIT) from pharmaceuticals grew 32 percent YoY, driven by healthy volume growth and strong traction in non-Ibuprofen APIs, which are broadening and diversifying our product portfolio.”

He further mentioned that in chemicals, the company achieved optimal capacity utilisation, reflecting improved demand and operational discipline. EBIT grew 37 percent YoY, supported by efficiency gains and sustained customer traction. This validates the strength of the company’s diversified business model and the meaningful contribution of both segments.

“Looking ahead, our focus remains on expanding our presence in regulated markets, strengthening our new product pipeline, deepening backward integration, and enhancing R&D capabilities. These measures will help us sustain growth momentum, enhance competitiveness, and deliver long-term value creation for our stakeholders,” he further added.